Directors’ Report Dr Mel Bridges  BAPPSC, FAICD  Non-Executive Director  Appointed 12 October 2007  Resigned 18 June 2014 Dr Mel Bridges has more than 30 years’ experience as a CEO and  public company director in the global biotechnology and healthcare  industry. During this period, he founded and managed successful  diagnostics, biotechnology and medical device businesses. He has  successfully raised in excess of $300 million investment capital in the  healthcare/biotech sector and been directly involved in over $1 billion  in M&A and related transactions. The businesses that Dr Bridges has founded have won numerous  awards including the Queensland Export Award, Australian Small  Business of the Year, Queensland Top 400, BRW’s Top 100 Fastest  Growing Companies for seven consecutive years and The Australian  Quality Award. Dr Bridges has an Honorary Doctorate from Queensland University of  Technology Other Current Directorships of Listed Companies ALS Ltd, Tissue Therapies Ltd. Former Directorships of Listed Companies in last three years Alchemia Limited (October 2003 to July 2013), Genetic Technologies  Limited (December 2011 to November 2012), Leaf Energy Limited  (August 2010 to September 2012), and Genera Biosystems Limited  (December 2008 to November 2010). Dr Bridges retired from the Board in June 2014. Dr John Chiplin PH.D.  Non-Executive Director Appointed 1 February 2010  Dr. Chiplin is CEO of Polynoma LLC, an immuno-oncology company  currently running one of the world’s largest (Phase III) melanoma trials.  Prior to Polynoma, he was the founding CEO of Arana Therapeutics,  a world leading antibody developer, and a director of Domantis, Inc.,  prior to their acquisition by Cephalon & GSK respectively. Dr Chiplin’s investment vehicle, Newstar Ventures Ltd., has funded  more than a dozen early stage companies in the past ten years. Dr.  Chiplin’s Pharmacy and Doctoral degrees are from the University of  Nottingham. In addition to Benitec Biopharma, he currently serves on  the board of ScienceMedia, Inc. and Adalta Pty.Ltd Other Current Directorships of Listed Companies : None Former Directorships of Listed Companies in the last three years Arana Therapeutics Ltd., Calzada Ltd., Healthlinx, Ltd., Progen  Pharmaceuticals Ltd., and Medistem, Inc. Mr Iain Ross BSc, CH.D.  Non-Executive Director Appointed 1 June 2010  Mr Ross brings over 30 years’ experience in the international life  sciences sector to the Board of Benitec. Following a career with  Sandoz, Fisons, Hoffman La Roche and Celltech, he has undertaken  and had input to a number of company turnarounds and start-ups as  a board member on behalf of banks and private equity groups. He has  led and participated in 4 IPOs, has direct experience of life science  Benitec Biopharma Ltd  Annual Report 2014 Page 3 Mr West is a Chartered Accountant with experience in the Biotech  sector. He is a Director and Audit Committee Chairman of UOWE  Limited (a business arm of Wollongong University), and a Director and  Audit Committee Chairman of IDP Education Pty Ltd and Education  Australia Limited. He worked at PWC and has held senior finance  executive roles in financial services and investment banking with  Bankers Trust, Deutsche Bank, NZI, and with other financial institutions. Mr Greg West CA  Appointed 26 May 2011  COMPANY SECRETARY Other Current Directorships of Listed Companies:  None Former Directorships of Listed Companies in last three years:  None He obtained his PhD in 1987 for work performed at CSIRO on the  characterisation of the keratin composition of the developing wool  fibre. He carried out postdoctoral research at the Children’s Medical  Research Foundation, Sydney, on the role of glycoprotein expression in  neuronal development. In 1989 he became Principal Scientific Officer  and Manager of the Centre for Immunology, St Vincent’s Hospital,  Sydney. Over the past 15 years Dr French has been extensively  involved in Australia’s biotechnology industry, initially founding the  stem cell company Cryosite (ASX:CTE), and then taking up leadership  roles at other biotechnology companies prior to joining Benitec in 2009  as its Chief Scientific Officer. Peter was appointed Chief Executive  Officer of Benitec in June 2010 and Managing Director in August 2013. Peter French is a cell and molecular biologist who has been  extensively involved in both basic and clinical medical research  and commercialisation of biological intellectual property. He has  an MBA in Technology Management and a PhD in cell biology. Dr  French is a Past President of the Australia and New Zealand Society  for Cell and Developmental Biology, and represented Australia’s  biological scientists on the Board of FASTS, Australia’s peak  government lobbying organization for science and technology. Dr  French has conducted cell and molecular research in a broad range  of areas relevant to Benitec’s DNA-directed RNAi based therapeutic  technology, including cancer, HIV/AIDS, neurobiology, immunology and  inflammatory disease. Dr Peter French  MBA, PH.D. Chief Executive Officer and Managing Director Appointed 26 August 2013 CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR Other Current Directorships of Listed Companies Ark Therapeutics Group plc, Tissue Therapies Limited, Novogen Limited  Former Directorships of Listed Companies in last three years:  Coms plc He is a Qualified Chartered Director and currently he is Chairman of  Ark Therapeutics Group plc (LSE); Biomer Technology Limited and  Pharminox Limited; and a non-executive director of Tissue Therapies  Limited (ASX), Novogen Limited (ASX) and Anatata Lifesciences  Limited. He is also Vice Chairman of the Council of Royal Holloway,  University of London.  mergers and acquisitions both in the UK and USA and has raised more  than £250m in the biotech sector.